🧬 A promising new step in the fight against pancreatic cancer Researchers are developing cancer vaccines designed to train the immune system to recognize and attack pancreatic cancer cells. One experimental vaccine targeting common KRAS mutations produced an immune response in 90% of participants in an early Phase 1 study involving people at high risk of pancreatic cancer. The immune response remained detectable in some participants for up to two years. Another personalized mRNA vaccine approach has also shown encouraging results. It is designed using information from an individual patient's tumor, helping the immune system recognize specific cancer-related targets. In an early study, some patients developed long-lasting cancer-targeting T-cell responses, with follow-up extending to several years. These results are exciting because pancreatic cancer has historically been difficult to treat with immunotherapy. Cancer vaccines could potentially give the immune system a more precise way to recognize cancer cells while creating immune memory that lasts over time. However, Phase 1 results are still preliminary. These studies mainly examine safety and immune responses, and they are not enough to prove that a vaccine can prevent pancreatic cancer or cure people who already have it. Larger clinical trials will be needed to determine how effective these vaccines are and whether they can improve long-term outcomes. #space #science #fact #facts